These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. IDH1 mutation diminishes aggressive phenotype in glioma stem cells. Yao Q; Cai G; Yu Q; Shen J; Gu Z; Chen J; Shi W; Shi J Int J Oncol; 2018 Jan; 52(1):270-278. PubMed ID: 29115585 [TBL] [Abstract][Full Text] [Related]
8. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment. Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546 [TBL] [Abstract][Full Text] [Related]
9. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma. Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922 [TBL] [Abstract][Full Text] [Related]
10. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158 [TBL] [Abstract][Full Text] [Related]
11. An in vivo patient-derived model of endogenous IDH1-mutant glioma. Luchman HA; Stechishin OD; Dang NH; Blough MD; Chesnelong C; Kelly JJ; Nguyen SA; Chan JA; Weljie AM; Cairncross JG; Weiss S Neuro Oncol; 2012 Feb; 14(2):184-91. PubMed ID: 22166263 [TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. Raghunathan A; Olar A; Vogel H; Parker JR; Coventry SC; Debski R; Albarracin CT; Aldape KD; Cahill DP; Powell SZ; Fuller GN Ann Diagn Pathol; 2012 Aug; 16(4):255-9. PubMed ID: 22445362 [TBL] [Abstract][Full Text] [Related]
13. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma. Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553 [TBL] [Abstract][Full Text] [Related]
14. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826 [TBL] [Abstract][Full Text] [Related]